http://bit.ly/2AbPxuj

The drug maker on Saturday said the USFDA has issued a Complete Response Letter (CRL) regarding the new drug application for Ryaltris (olopatadine hydrochloride [665 mcg] and mometasone furoate.

from Markets http://bit.ly/2LgnBvP

Comments

Popular posts from this blog

IIT PhDs in demand for high-end R&D jobs

India Inc turn to non-bank routes for funding